Products - Blood and bone marrow cancers | Topic | NICE

Showing 38 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Waldenstrom’s macroglobulinaemia - ibrutinib [ID884]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
22 November 2017
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 April 2026
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 April 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 May 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 June 2026
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
7 April 2026
Expected publication date:
18 June 2026
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 July 2026
Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 February 2027
Decitabine–cedazuridine with venetoclax for untreated acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 March 2027
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
14 April 2026
Expected publication date:
6 May 2027
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 June 2027
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
16 April 2026
Expected publication date:
TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments (review of TA987) [ID6619]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
14 April 2026
Expected publication date:
TBC
Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma
Status:
In development
Programme:
HealthTech guidance
Expected publication date:
TBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC